Tas, F. And Erturk, K. 2019. BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha. CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.84, no.3 , 521-526.

Tas, F., & Erturk, K., (2019). BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha. CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.84, no.3, 521-526.

Tas, Faruk, And Kayhan ERTÜRK. "BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha," CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.84, no.3, 521-526, 2019

Tas, Faruk And Erturk, Kayhan. "BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha." CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.84, no.3, pp.521-526, 2019

Tas, F. And Erturk, K. (2019) . "BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha." CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.84, no.3, pp.521-526.

@article{article, author={Faruk TAŞ And author={Kayhan ERTÜRK}, title={BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha}, journal={CANCER CHEMOTHERAPY AND PHARMACOLOGY}, year=2019, pages={521-526} }